Last reviewed · How we verify
VIS410 low dose
At a glance
| Generic name | VIS410 low dose |
|---|---|
| Sponsor | Visterra, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Efficacy and Safety of IV VIS410 Plus Oseltamivir Versus Oseltamivir in Hospitalized Adults With Influenza A (PHASE2)
- Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |